Wanbury Limited (WANBURY) fundamentals
Wanbury Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as WANBURY (ISIN INE107F01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Wanbury Limited does
Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.
Valuation and market data
| Last close | ₹241.45 |
|---|---|
| Market capitalisation | ₹791 crore |
| Enterprise value | ₹967 crore |
| P/E (TTM) | 0.00 |
| Price to book | 13.34 |
| Price to sales (TTM) | 1.21 |
| Book value per share | ₹18.09 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jan 29 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹651 crore | ₹60 crore | ₹66 crore | 0.00 |
| Mar 2025 | ₹603 crore | ₹30 crore | ₹31 crore | 9.32 |
| Mar 2024 | ₹579 crore | ₹31 crore | ₹30 crore | 9.29 |
| Mar 2023 | ₹501 crore | ₹-10 crore | ₹-10 crore | -3.18 |
| Mar 2022 | ₹513 crore | ₹81 crore | ₹81 crore | 25.29 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 43.0% |
|---|---|
| Foreign institutions (FII) | 0.9% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.1% |
| Retail and others | 56.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.